

# Neurotech

23 September 2020

## Neurotech Commences Landmark In Vitro Trials of Unique Cannabis Strains

### Highlights

- **NTI commences independent in vitro testing (using human derived cell lines) to analyse the bio-efficacy on 7 key cannabis strains after recent analytical program comprising 80 samples**
- **Studies to assess activities of newly discovered cannabinoids including CBDP and CBDB – making Neurotech one of the first organisations globally to carry out cell line studies on these new cannabinoid varieties**
- **In vitro testing to be carried out at three leading independent laboratories – Monash University, University of Wollongong and RMIT**
- **Testing expected to be complete by November 2020**
- **If testing is successful, NTI will commence clinical trials with an Australian university, utilising Dolce cannabis strains and its own proprietary Mente autism neurofeedback device which analyses brain wave activity**

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to announce it has commenced in vitro cell studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of key cannabis strains. The trials are part of Neurotech's research into the potential of cannabinoids for medicinal use in treating neurological disorders including autism, epilepsy and ADHD.

Commencement of trials follows ACS Laboratories' ("ACS") genetic profiling and full potency analysis on 80 cannabis samples from Australian cannabis grower Dolce Cann Global Pty Ltd ('Dolce'), with results from this work supporting Neurotech's plans.

Neurotech Chairman Mark Davies said the in vitro studies would assess the activities of the lead Dolce strains, determined by the earlier genetic profiling, in human neuroblast cells as well as microglial cells and assays.

"Neurotech is one of the first groups in the world to carry out these cell lines studies on newly discovered cannabinoid varieties including CBDA, CBDP and CBDB. These studies will be an exciting development and contribution to the medical cannabis research field.

"These studies will also assess the activities of the newly discovered cannabinoids; CBDP and CBDB. In vitro studies are a powerful way of ascertaining the bio-efficacy of these strains prior to commencing clinical trials. These studies will enable NTI to determine the safety, bio-efficacy and dose response."

---

#### Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

[www.neurotechinternational.com](http://www.neurotechinternational.com)

Mr Davies said the in vitro trials would be completed across three independent scientific laboratories, Monash University, University of Wollongong and RMIT in Melbourne.

“All three facilities are internationally recognised for their outstanding work in the field of cannabinoid research and development, as well as developing the most relevant human derived cell lines relating to neuronal development. These cell lines are a powerful and effective tool in assessing bio-efficacy of actives and determining mechanism of action for our selected key cannabis strains.”

Neurotech expects in vitro trials to be complete in November. Based on the findings of this work, Neurotech plans to commence clinical trials, using the key cannabis strains from Dolce and its own proprietary Mente autism neurofeedback device which analyses brain wave activity.

### **Authority**

This announcement has been authorised for release by the Board of Directors of the Company.

### **Further Information**

Mark Davies  
Chairman  
md@1861capital.com.au  
+61 413137887

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 410 667 844

### **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.